Arbutus Biopharma Corporation (ABUS)

[Cave In Temptor]

Less to zMapp 5-days article that meets the eye

As always, the devil is in the detail with Qiu's 2014 article (link) on reversing Ebola disease with zMapp up to 5 days post infection...
Don't count on news reporters to notice them.

In short, these apparently great results are to ponder in view of lower virus exposure and near double doses of treatment...

Recall ZMapp is a combo of 2 MAbs from ZMabb and 1 from MB-003 (underlined below), that all target EBOV's GP (surface Glyco-Protein).
-- Experiment 1
50 mg/ kg of ZMapp (13C6, 2G4, 4G7 MAb combo) or ZMapp2 (13C6, 1H3, 2G4 MAb combo) every 3 days following infection by 2,512 PFU EBOV.
Survival was 100% (6/6) if initiated on day 3 for ZMapp1 and 83% (5/6) for ZMApp2.

-- Experiment 2
50 mg/ kg of ZMapp every 3 days following infection by 628 PFU EBOV.
Survival was 100% (6/6) if initiated on day 3.
Survival was 100% (6/6) if initiated on day 4.
Survival was 100% (6/6) if initiated on day 5.


Going into prior data on the components of ZMapp:

In 2012, Qiu gave 25 mg/kg of ZMabb (1H3, 2G4, 4G7 MAb combo) every 3 days following infection by 1,000 PFU EBOV.
Survival was 100% (4/4) if initiated 24 hrs post infection.
Survival was 50% (2/4) if initiated at 48 hrs post infection.

In 2012, Olinger gave 50 mg/kg of MB-003 (13C6, 13F6, 6D8 MAb combo) 4 times following infection by 1,000 PFU EBOV.
Survival was 67% (2/3) if initiated 24 hrs post infection.
Survival was 67% (2/3) if initiated 48 hrs post infection.